Neurogene Inc. (NGNE) SEC Filings & Earnings Calls

Clinical trial failure risk

“In November 2024, the third participant receiving the 3E15 vg dose of NGN-401 died following complications from a rare hyperinflammatory syndrome associated with systemic exposure to high doses of AAV, and we discontinued use of that dose.” · word for word

Going concern risk

“The Company expects to incur substantial and increasing losses in future periods as the Company advances its products through its clinical and regulatory process and will rely on outside capital to fund its operations for the foreseeable future.”

Dependence on single product candidate

“We are substantially dependent on the success of our most advanced product candidate, NGN-401, and our clinical trial of NGN-401 may not be successful.” · word for word

Clinical trial risk; topline data expected 2H 2027.

“Topline data from Embolden registrational trial anticipated in 2H 2027.” · word for word

Regulatory approval risk; BLA submission pending.

“Initiated PPQ campaign to support BLA submission for NGN-401.” · word for word

High cash burn; net loss increasing.

“Net loss was $34.5 million for the three months ended June 30, 2026, compared to $22.0 million for the three months ended June 30, 2025.” · word for word

Dilution to existing shareholders from issuance of 3.5M shares plus pre-funded warrants and option exercise.

“3.5M shares at $30.00, 666,666 pre-funded warrants, and full exercise of 624,999 share option.”

Clinical data is from a small Phase 1/2 trial (N=10); registrational trial topline data not expected until 2H 2027; regulatory and commercial risks remain.

“Phase 1/2 trial with 10 participants; registrational trial dosing complete but topline data in 2H 2027.”

No data results disclosed; regulatory and commercial risks remain high.

“No efficacy or safety data provided in this filing.”

Clinical trial risk: NGN-401 is the sole pipeline asset; any safety or efficacy issues could materially impact the company.

“NGN-401 is an investigational AAV9 gene therapy in late-stage clinical development; no HLH cases at 1E15 vg dose but limited data” · word for word

Regulatory risk: FDA approval for NGN-401 is uncertain and could be delayed or denied.

“Potential best-in-class, one-time treatment for Rett syndrome; regulatory pathway not yet defined” · word for word

Clinical trial failure risk

“The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, ... risks of failure of preclinical studies, clinical studies and clinical trials” · word for word

Funding dependency

“Management expects to incur substantial and increasing losses in future periods ... and will rely on outside capital to fund its operations for the foreseeable future.” · word for word

Clinical trial dependency

“These PSUs were eligible to vest as to 50% of such award upon the achievement of certain performance goals related to our clinical trial for NGN-401 for the treatment of Rett syndrome prior to June 30, 2025, which was deemed achieved in June 2025, and the remaining 50% will vest upon the achievement of additional performance goals related to clinical develop” · word for word

Clinical-stage biotech with no approved products; net loss increasing; reliance on NGN-401 success.

“Net loss increased to $90.4M from $75.1M; R&D expenses increased; no revenue from product sales.”

Clinical trial failure risk

“We have a limited operating history, have not completed any clinical trials, and have no products approved for commercial sale” · word for word

Capital requirement risk

“We will require substantial additional capital to finance our operations in the future.” · word for word

Dependence on single product candidate

“We are substantially dependent on the success of our most advanced product candidate, NGN-401” · word for word

Regulatory approval uncertainty

“The regulatory approval processes of the U.S. Food and Drug Administration (FDA) and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable.” · word for word

Clinical trial risk remains; Breakthrough Therapy does not guarantee approval

“Forward-looking statements caution about clinical trial outcomes and regulatory approval”

Cash burn risk

“The Company used cash in operations of $59.7 million and $53.1 million for the nine months ended September 30, 2025 and 2024, respectively, and had an accumulated deficit of $327.9 million as of September 30, 2025.” · word for word

Dependence on external financing

“Management expects to incur substantial and increasing losses in future periods as the Company advances its products through its clinical and regulatory process and will rely on outside capital to fund its operations for the foreseeable future.” · word for word

Clinical-stage company with no approved products or revenue; depends on trial success and financing.

“No revenue reported; net loss of $21M; cash burn rate implies need for future capital.”

Gene therapy manufacturing and regulatory risks; FDA feedback and trial enrollment uncertainties.

“NGN-401 is investigational; FDA START program and RMAT designation but no guarantee of approval.”

Clinical-stage company with no approved products; depends on trial success and regulatory approval.

“No revenue; early-stage clinical data; FDA approval uncertain.”

Clinical-stage company with no approved products; depends on trial success and regulatory approval.

“No revenue; early-stage clinical data; FDA approval uncertain.”